Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SLGL | US
-1.45
-1.93%
Healthcare
Biotechnology
30/06/2024
17/04/2026
73.87
75.70
77.22
72.83
Sol-Gel Technologies Ltd. a clinical stage specialty pharmaceutical company focuses on identifying developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo a novel once-daily non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210 which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610 a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona Israel.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
68.5%1 month
130.9%3 months
110.0%6 months
95.1%-
9.34
0.54
0.04
0.03
0.24
0.13
-
-16.52M
2.06B
2.06B
-
29.89
-
814.60
-35.85
0.95
0.69
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
15.16
Range1M
31.61
Range3M
49.71
Rel. volume
0.63
Price X volume
2.97M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Arcus Biosciences Inc | RCUS | Biotechnology | 24.25 | 2.22B | 2.80% | n/a | 1.73% |
| Adeptus Health Inc | ADPT | Biotechnology | 14.47 | 2.13B | 2.77% | n/a | 93.65% |
| IRON | IRON | Biotechnology | 71.77 | 2.13B | 3.34% | n/a | 0.38% |
| Day One Biopharmaceuticals Inc. Common Stock | DAWN | Biotechnology | 21.47 | 2.11B | 0.09% | n/a | 0.06% |
| Syndax Pharmaceuticals Inc | SNDX | Biotechnology | 24.23 | 2.06B | 1.76% | n/a | 0.26% |
| Sarepta Therapeutics Inc | SRPT | Biotechnology | 21.55 | 2.06B | 1.79% | 169.44 | 127.19% |
| Dynegy Inc | DYN | Biotechnology | 20.41 | 2.05B | 2.51% | n/a | 3.32% |
| AnaptysBio Inc | ANAB | Biotechnology | 67.51 | 2.04B | 0.91% | n/a | 3835.68% |
| PROK | PROK | Biotechnology | 2.18 | 2.00B | 11.79% | n/a | -0.69% |
| Agios Pharmaceuticals Inc | AGIO | Biotechnology | 35.14 | 2.00B | 0.63% | n/a | 9.78% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| HNI Corporation | HNI | Building Products & Equipment | 37.94 | 1.79B | 6.16% | 22.12 | 76.47% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 15.19 | 1.52B | 2.50% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 41.95 | 1.32B | 1.52% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 33.74 | 976.94M | 4.14% | 22.53 | 56.33% |
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.54 | 805.08M | 5.73% | 11.62 | 116.21% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.34 | 732.76M | 5.14% | 65.18 | 77.00% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 17.37 | 724.04M | 5.53% | 42.05 | 64.69% |
| Ennis Inc | EBF | Building Products & Equipment | 21.67 | 563.50M | 1.69% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 26.54 | 530.55M | 7.32% | n/a | 1.50% |
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 23.4 | 388.61M | 6.32% | 34.27 | 26.82% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.24 | - | Cheaper |
| Ent. to Revenue | 0.13 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.54 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 109.95 | - | Riskier |
| Debt to Equity | 0.04 | -1.23 | Expensive |
| Debt to Assets | 0.03 | 0.25 | Cheaper |
| Market Cap | 2.06B | - | Emerging |